VERAXA Biotech (NASDAQ: VRXA) announced on July 29, 2026, an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047.
The company said its BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present. VERAXA also highlighted proprietary click chemistry, conjugation, linker and payload technologies intended to enhance the safety, efficacy and manufacturability of its antibody-drug conjugate and T-cell engager pipelines, reinforcing its long-term strategy to develop next-generation oncology therapeutics.
This expansion of intellectual property is significant for the biotechnology industry as it strengthens the company's competitive position in the development of bispecific T cell engagers and bispecific ADCs. By securing patent protection through 2047, VERAXA aims to ensure long-term exclusivity for its innovative platforms, which could lead to more targeted and safer cancer treatments. For investors, this news underscores the company's commitment to building a robust patent estate, potentially increasing its valuation and attractiveness for partnerships. For patients, the advancement of these technologies could mean access to therapies with improved selectivity, reducing harmful side effects associated with traditional cancer treatments.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. The latest patent filings are a key component of VERAXA's strategy to rapidly advance its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.
For more details on the full press release, visit https://ibn.fm/BqhFS. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
